항 파킨슨씨 약물 Anti-Parkinson Drug.

Slides:



Advertisements
Similar presentations
Parkinson Disease (PD) Treatment Update. Outlines The Basics: – PD Introduction and motor symptoms. – DDx not to miss. – Different classes of Anti PD.
Advertisements

The Pharmacology of Parkinson’s Disease
Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Diagnosis and Management of Parkinson’s Disease
Pharmacology of Drugs Used in Parkinson’s Disease Jose Paciano B.T. Reyes, FPNA ASMPH January 27, 2011.
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
ILOs At the end of this lecture you will be able to:- Revew the symptoms and pathophysiology of parkinsonism. Detail on the pharmacology of drugs used.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Parkinson’s Disease: A Brief Overview
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Initial Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Parkinson’s Disease Busra Berika Yucel
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Parkinson ’ s A Review and Practical Guide to a Common and Complex Disease.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Objectives Description of Parkinson's disease
Parkinson’s Disease. The basal ganglia, through the action of dopamine, are responsible for planning and controlling automatic movements of the body,
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Drugs For Parkinson's Disease. History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy.
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
How do drugs affect the synapse?
Parkinson’s Disease Slide Library Version All Contents Copyright © WE MOVE 2001 Pharmacologic Treatment of Parkinson’s Disease Part.
Parkinson’s Disease Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.
PARKINSON’S DISEASE By: AARUSHI JAIN AMRUTA KAMBLE ANNETT MARY JACOB AVANTI DEO M.Sc. PRIST (09-11)
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
How are medicines developed?. What is it? What’s inside?
By Prof. Hanan Hagar Pharmacology unit Medical College.
Parkinson's Disease ILOs
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Drugs in parkinsonism ilos
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
CNS -Antiparkinsonian Drugs Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of.
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Dostálová Zuzana, 3. C.  Ancient Egypt, 12. century BC  James Parkinson- 1817, The Essay of Shaking Palsy  Funk- 1911, L-DOPA- the cure.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Drugs used in Parkinson disease Historical Perspective Dr. James Parkinson ( ) 1817 “ involuntary tremulous motion ” “ pass from a walking.
Drug Therapy for Parkinson’s Disease
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Parkinson’s Disease The basal ganglia, through the action of dopamine, are responsible for planning and controlling automatic movements of the body, such.
Drugs for Parkison’s disease and Alzheimer’s disease Drugs for Parkison’s disease and Alzheimer’s disease Department of pharmacology.
Drugs Used for Parkinson’s Disease
Parkinsonism.
DRUGS FOR PARKINSONISM
Pharmacologic Management of Parkinson disease (PD)
Drugs of Anti-Parkinson’s disease
Lecture 3 Dr.Narmin Hussen
Drugs for Parkinson’s Disease
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
Anti-parkinsonism Drugs
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Chapter 17 Antiparkinson Drugs.
Presentation transcript:

항 파킨슨씨 약물 Anti-Parkinson Drug

파킨슨씨병 의 날 4월 11일

Substansia Nigra (흑질)

History of Parkinson’s Disease Parkinon’s small but famous publication, "Essay on the Shaking Palsy", appeared in 1817, 7 years before his death in 1824.

Epidemiology Average incidence is 20 per 100,000 in North America 1 Million affected in the United States 50,000 new cases per year Cost estimated to exceed $5.6 Billion annually

Four Typical Signs of Parkinsonism Diagnostic Features Four Cardinal Signs Tremor Rigidity Akinesia and bradykinesia Postural instability Four Typical Signs of Parkinsonism

Reduction of inhibitory Dopaminergic Neron Parkinson’s Disease Reduction of inhibitory Dopaminergic Neron Imbalance of Ach & DA Pakinson Syndrome

Positron-Emission Tomography

Antiparkinson’s Drug Treatment for Parkinson’s disease Pakinson syndrome Dopamine receptor agonist DA Synthesis MAO-B inhibitor Anti-Muscarinic agent

Parkinson’s disease 예방

담배와 파킨슨씨병

Drug Interaction

Structure of Drug for Parkinson’s Disease

Why L-Dopa instead of DA? If dopamine is too polar to cross the BBB, how can L-DOPA cross it?

Trojan horse Approach for Carrier Protein Recognized as amino acid by carrier protein

The Effect of Carbidopa on the metabolism of L-Dopa

The Action of Selegiline in the metabolism of Dopamine

The mechanism of Entacaone as Anti-parkinsonism

Muscarine Antagonist ☞ Chemical Name: 3-(1-Piperidyl)-1-cyclohexyl-1-phenyl-1-propanol HCl a-Cyclphexyl-a-phenyl-1-piperidinepropanol HCl ☞ Trade Name: 트리헥산 정 (태극), 염산트리헥시딜 정 (장우), Artane® (Lederle) 24

Retrosynthesis of Trihexylphenidyl

Muscarine Antagonist ☞ Chemical Name: :1-(Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-phenyl-3-(piperidin- 1-yl)propan-1-ol HCl :a-(2-Norbonenyl)-a-pheny-1-piperidinepropanol HCl ☞ Trade Name: 아톨 정 (유나이티드), 염산비페리덴 정 (풍림), Akineton® (Abbot)

Muscarine Antagonist

Mannich Reaction

Dopamine Agonist ☞ Chemical Name: :(S)-2-Amino-3-(3,4-dihydroxyphenyl)propanic acid ☞ Trade Name: 레보다 서방정 (산도스), 스다레보 필름코팅 정 (노바티스), 씨네메트/씨알정 (MSD), 콤비도파 서방정(노바티스) Stalevo® (a mixture of L-DOPA, carbidopa, entacapone, Orion

Side Effect of levodopa

Drug Interactions

Why L-Dopa, not Dopamine ? Not cross the BBB Cross the BBB In Brain

Retro synthesis of L-DOPA L-Tyrosine

L-DOPA

Regiochemistry of Bayer-Villiger-Oxidation

Retrosyntheis of L-DOPA(II)

L-DOPA (Dopamine Agonist)

Carbidopa ☞ Chemical Name: :(S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid ☞ Trade Name: : Stalevo® (a mixture of L-DOPA, carbidopa, entacapone, Orion

Levodopa & Carbidopa Nausea and Vomiting

Retrosynthesis of Carbidopa

Dopamine Agonist

Dopamine Agonist

Dopamine Agonist

Dopamine Agonist Ropinirole ☞ Chemical Name: 4-[2-(Dipropylamino)ethyl-1,3-dihydro-2H-indol-2-one ☞ Trade Name: : RopiniroleHCl: 뉴큅 정 (유한), 로큅 정 (대웅), 로피맥스 전 (고려), 파로킨 정 (현대), 도파로핀(일동), 로킨스 정(신풍). 리큅피디 정 (글라고스미스클라인) : Ropinirole: 리큅 정 (글락소스미스클라인, ropinirole), Requip (GSK)

Retrosynthesis of ropinirole OH

Synthesis of Ropinirole Dopamine Agonist Synthesis of Ropinirole

selegiline (R)-N-methyl-N-(1-phenylpropan-2-yn)-1-amine 유멕스 정(사노피-아벤티스 코리아), 아오비 정(초당), Eldepryl(Somerset)

Retrosynthesis of Selegiline

Synthesis of Selegiline Dopamine Agonist Synthesis of Selegiline

Asymmetric Synthesis of Selegiline Dopamine Agonist Asymmetric Synthesis of Selegiline

Entacapone Dopamine Agonist ☞ Chemical Name: (E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)-propenamide ☞ Trade Name: : 콤탄 정 (노바티스), 스타레보 필름코팅 정 (L-DOPA 및 Carbidopa 와 복합제, 노바티 스), Comtan® (Orion)

Retrosynthesis of Entacapone

Synthesis of Entacapone Dopamine Agonist Synthesis of Entacapone